Esperion Therapeutics competitive analysis

Loading summary...

Explore Esperion Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
Nov 1, 2023Fixed Dose Combinations Comprising Etc1002 And One Or More Statins For Treating Or Reducing Cardiovascular Risk6

Latest publications and patents of Esperion Therapeutics New

Explore the latest publications and patents granted to Esperion Therapeutics, showcasing their recent innovations and technological advancements.

Last updated on: Oct 19, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Esperion Therapeutics

Nov 1, 2023Fixed Dose Combinations Comprising Etc1002 And One Or More Statins For Treating Or Reducing Cardiovascular RiskGranted And Under Opposition

Latest PTAB cases involving Esperion Therapeutics

Discover the latest PTAB cases involving Esperion Therapeutics, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Esperion Therapeutics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ESPERION THERAPEUTICS - 6 - -
GALENICUM HEALTH SLU2713 - -
HOEFER & PARTNER PATENTANWALTE MBB13 - - -
INTAS PHARMACEUTICALS1643 -